Profile data is unavailable for this security.
About the company
Zhejiang Orient Gene Biotech Co., Ltd. is a China-based company principally involved in the research, development, manufacture and sales of in-vitro diagnostic products. The Company's main products are Point of Care Testing (POCT) instant diagnostic reagents, which are mainly used in drug testing, infectious disease testing, eugenic testing, tumor marker testing and cardiac marker testing. The Company also engages in the manufacture and sales of biochemical diagnostic reagents used for dry biochemical diagnostics and biochemical fluid diagnostics. The Company operates its businesses in Mainland China, America, Europe, Asia, Africa and Oceania.
- Revenue in CNY (TTM)825.60m
- Net income in CNY-587.36m
- Incorporated2005
- Employees2.23k
- LocationZhejiang Orient Gene Biotech Co LtdNo. 3787 East Section of Sunshine AvenueDipu Neighborhood, Anji CountyHUZHOU 313300ChinaCHN
- Phone+86 5 725300267
- Fax+86 5 725300267
- Websitehttps://www.orientgene.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hangzhou Alltest Biotech Co Ltd | 812.78m | 276.54m | 5.25bn | 1.09k | 18.94 | 1.32 | -- | 6.46 | 3.50 | 3.50 | 10.26 | 50.02 | 0.198 | 2.21 | 6.97 | 743,626.50 | 6.74 | 23.35 | 7.22 | 26.83 | 53.69 | 58.34 | 34.03 | 39.07 | 10.46 | -- | 0.0022 | 29.79 | -77.73 | 32.59 | -84.75 | 26.19 | 72.77 | -- |
| Shanghai Sanyou Medical Co Ltd | 434.20m | 37.87m | 5.26bn | 466.00 | 147.82 | 2.75 | -- | 12.11 | 0.1432 | 0.1432 | 1.71 | 7.69 | 0.1951 | 0.6191 | 5.15 | 931,756.40 | 2.09 | 9.42 | 2.41 | 10.85 | 70.72 | 87.15 | 10.73 | 29.78 | 3.27 | -- | 0.0135 | 16.21 | -29.08 | 15.67 | -49.91 | 8.99 | -15.60 | -- |
| Innovita Biological Technology Co Ltd | 720.40m | 332.01m | 5.82bn | 404.00 | 17.46 | 2.85 | -- | 8.07 | 2.44 | 2.44 | 5.30 | 14.98 | 0.3584 | 3.18 | 9.16 | 1,783,177.00 | 16.52 | -- | 17.42 | -- | 80.70 | -- | 46.09 | -- | 16.01 | -- | 0.001 | -- | 7.03 | -- | 15.44 | -- | -- | -- |
| Zhende Medical Co Ltd | 4.04bn | 205.34m | 6.17bn | 6.72k | 30.14 | 1.11 | -- | 1.53 | 0.7684 | 0.7684 | 15.19 | 20.95 | 0.5191 | 3.12 | 6.43 | 601,941.30 | 2.85 | 17.13 | 3.61 | 23.54 | 34.16 | 38.05 | 5.49 | 17.33 | 1.80 | 38.53 | 0.1465 | 29.85 | -32.76 | 23.63 | -70.87 | 8.79 | 21.46 | 47.58 |
| Zhejiang Orient Gene Biotech Co Ltd | 825.60m | -587.36m | 6.49bn | 2.23k | -- | 0.9432 | -- | 7.86 | -2.93 | -2.93 | 4.14 | 34.13 | 0.0949 | 1.17 | 3.19 | 370,058.00 | -7.18 | 29.62 | -8.27 | 38.29 | 39.26 | 59.69 | -75.73 | 35.82 | 3.71 | -- | 0.0744 | 19.24 | -90.65 | 23.46 | -119.23 | -- | 121.04 | -- |
| Shanghai Aohua Phtlctrcty Endscp Co Ltd | 750.04m | 49.97m | 6.92bn | 1.09k | 127.80 | 5.00 | -- | 9.23 | 0.4023 | 0.4023 | 5.56 | 10.27 | 0.4682 | 1.01 | 3.34 | 686,850.10 | 3.26 | 4.37 | 3.66 | 4.80 | 68.88 | 69.25 | 6.97 | 10.91 | 3.33 | -- | 0.0815 | 31.51 | 52.29 | 34.25 | 166.42 | -- | 20.42 | -- |
| Shenzhen Lifotronic Technology Co Ltd | 1.19bn | 381.08m | 7.06bn | 1.48k | 18.51 | 3.62 | -- | 5.92 | 0.8909 | 0.8909 | 2.79 | 4.55 | 0.4834 | 2.27 | 7.49 | 805,792.80 | 15.37 | 13.82 | 21.09 | 16.33 | 67.06 | 61.01 | 31.79 | 26.10 | 2.25 | -- | 0.2434 | 41.51 | 16.55 | 28.78 | 30.66 | 32.27 | -7.91 | -- |
| HOB Biotech Group Corp Ltd | 401.29m | 35.26m | 7.76bn | 550.00 | 219.11 | 9.50 | -- | 19.33 | 0.5614 | 0.5614 | 6.35 | 12.95 | 0.4102 | 1.37 | 8.23 | 729,609.80 | 3.60 | 9.94 | 4.33 | 12.10 | 61.87 | 65.30 | 8.79 | 19.53 | 0.9438 | 39.42 | 0.1192 | 32.59 | 23.10 | 14.38 | 13.64 | 3.34 | 46.19 | -- |
Data as of Nov 15 2024. Currency figures normalised to Zhejiang Orient Gene Biotech Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
8.94%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 4.45m | 2.21% |
| Rongtong Fund Management Co., Ltd.as of 30 Jun 2024 | 4.29m | 2.13% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2024 | 3.45m | 1.71% |
| China Merchants Fund Management Co., Ltd.as of 30 Jun 2024 | 1.80m | 0.89% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 950.20k | 0.47% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2024 | 855.20k | 0.42% |
| Da Cheng Fund Management Co., Ltd.as of 30 Jun 2024 | 742.94k | 0.37% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2024 | 690.49k | 0.34% |
| The Vanguard Group, Inc.as of 02 Oct 2024 | 458.77k | 0.23% |
| Maxwealth Fund Management Co., Ltd.as of 30 Jun 2024 | 327.99k | 0.16% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
